Immuneel Therapeutics has announced partnerships with Impact Guru and CarePal Money to address access to cancer treatment in India by focusing on financing support for CAR T-cell therapy. The company stated that the collaborations are intended to improve financial access for patients from different income groups.
CAR T-cell therapy is used in the treatment of certain blood cancers, particularly in cases of relapsed or refractory disease. Immuneel Therapeutics noted that access to this therapy has been limited due to high upfront costs and the availability of financing options. Through this model, the company aims to address affordability and financial preparedness associated with advanced therapies in emerging markets.
As part of the partnership, Impact Guru will support patients and families by enabling fundraising through its digital crowdfunding platform. The platform will facilitate donation campaigns and awareness drives through a donor network of over 50 lakh contributors. CarePal Money will provide access to credit by connecting eligible patients with its network of non-banking financial company (NBFC) partners, offering loan and financing options for medical treatment. Immuneel Therapeutics will continue to deliver CAR T-cell therapies in India and will coordinate with both partners to align financial support with clinical care.
Commenting on the collaboration, Amit Mookim, Board Director and Chief Executive Officer, Immuneel Therapeutics, said, “Scientific innovation alone does not transform cancer care. Real impact comes when breakthrough therapies reach patients who need them most, regardless of financial circumstance. Through our partnerships with Impact Guru and CarePal Money, we are building a more holistic access ecosystem that combines clinical excellence with financial enablement, aligned with India’s ambitions in advanced therapeutics and universal health coverage.”
Piyush Jain, Co-Founder and CEO, CarePal Group and Impact Guru, said, “Healthcare innovation needs inclusive financing models. This partnership creates a dual pathway: patients can mobilise community support through Impact Guru’s crowdfunding platform while also accessing structured credit through CarePal Money’s NBFC partners. Together, this offers both flexibility and financial security at a critical time.”
Sahil Lakshmanan, Chief Business Officer, CarePal Money, said, “As medical innovation advances, healthcare financing must evolve alongside it. By institutionalising credit access for advanced therapies through our NBFC partnerships, we aim to reduce financial shock for families and support continuity of care.”
The partners stated that the collaboration outlines an access framework for emerging markets, combining cell and gene therapies with digital crowdfunding and healthcare lending. The initiative is intended to work alongside public health systems, insurance coverage, and future reimbursement pathways for CAR T-cell therapy, as these treatments become part of oncology care delivery.